As previously described by Ordonez et al. [20],we assessed whether there was a synergistic effect between HLA-DRB1*15:01 and the LILRA3 deletion in order to confer MS risk, but no significant epistatic interaction was observed (p = 0.36). Here, HLA-DRB1 is linked to myeloid sarcoma.